Company Information
Industry 制造业
Company Introduction 2009年12月11日,陕西康惠制药有限公司与自然人王延岭签订《发起人协议》,同意以发起设立的方式发起设立股份公司,公司设立时的注册资本为5,000万元人民币。2009年12月11日,陕西康惠制药股份有限公司召开创立大会暨第一次股东大会,审议通过公司创立的议案。2009年12月16日,上海上会会计师事务所有限公司出具上会师报字(2009)第1908号《验资报告》,对公司设立时的首次出资情况进行了验证。2009年12月24日,公司在陕西省工商行政管理局完成了工商设立登记手续,并领取了注册号为610000100257840号企业法人营业执照。 公司恪守“牵系生命质量,致力人类健康”的文化理念, 长期专注于医药健康产业,主要业务涵盖医药制造业(中成药、医药中间体、中药材及中药饮片)及医药流通业(生物制品、血液制品、药品的销售配送服务)领域。 公司主要业务以中成药品的研发、生产、销售为主,以生物制品(除疫苗)、血液制品、药品的销售配送业务为辅。公司中成药产品线主要涵盖皮肤科类、呼吸感冒类、妇科类、骨科类疾病的治疗领域,主营产品中消银颗粒、复方双花片、坤复康胶囊(片)及附桂骨痛胶囊列入国家医保目录;消银颗粒与枣仁安神颗粒列入国家基本药物目录。
Main Business 中成药品的研究、开发、生产与销售。
Legal Representative 王延岭
Top Executives
董事长:王延岭
董事:胡江,张俊民,侯建平,赵敬谊,杨瑾
独立董事:康玉科,窦建卫,叶崴涛
Top 5 Shareholder
Shareholder name Nature Holding Date
陕西康惠控股有限公司流通A股36.75%30/09/2024
TBP Traditional Medicine Investment Holdings(H.K.)Limited流通A股14.81%30/09/2024
王延岭流通A股6.66%30/09/2024
曹志洪流通A股1.45%30/09/2024
王艳敏流通A股0.66%30/09/2024
Company Secretary 董娟
Solicitors 北京市金杜律师事务所
Auditors 上会会计师事务所(特殊普通合伙)
Tel No 029-33347561
Fax No 029-33347561
Website www.sxkh.com
Email irsxkh@163.com
Company Address
Register: 陕西省咸阳市秦都区高新技术产业开发区彩虹二路
Office: 陕西省咸阳市秦都区胭脂路36号
Listing Date 21/04/2017
Shares Capital
Shares Capital: 99,880,000
Total A Share: 99,880,000
Listed A Share: 99,880,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.260
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 9.504
Market Capitalization(RMB) 1.447B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.